High‐risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV
HIV Medicine · 2025
DOI: 10.1111/hiv.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Merle Henderson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Imperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK. Hauptthemen laut MEDLINE: Papillomavirus Infections, HIV Infections, Cervix Uteri, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British HIV Association, Imperial Health Charity, NIHR Imperial Biomedical Research Centre.
Abstract (Originalsprache)
Objectives
Human papillomavirus (HPV)‐associated cervical cancer risk is greater in people with HIV, although this has been at least partially attenuated by antiretroviral medication, enhanced cervical screening and HPV vaccination. People with perinatally acquired HIV may remain at higher risk due to lifelong immunosuppression and potentially reduced vaccine effectiveness. In this study in people with a cervix with perinatally acquired HIV, we explored cervical high‐risk HPV (hrHPV) prevalence and HPV serostatus.
Methods
Participants were recruited from a London HIV service between 2020 and 2022. Cervical samples from those sexually active were analysed for hrHPV (Cepheid GeneXpert) and cytology, and, if abnormal, a referral was made to colposcopy. Serum samples were tested for antibodies against HPV6/11/16/18/31/33/45/52/58. A self‐reported questionnaire including HPV vaccination history was completed.
Results
Fifty‐seven people were recruited with a median age of 25 years (range 18–34). Of those providing a cervical sample, 15/47 (32%) were hrHPV‐positive and 12/40 (30%) had abnormal cytology; 1/17 referred for colposcopy had CIN2 (6%); 7/15 (47%) with hrHPV were below the national screening age of 24.5 years (range 19–23), and 9/15 (60%) reported previous HPV vaccination. No vaccinated participants had hrHPV16/18. Of those vaccinated, 37/39 (95%) were seropositive for HPV16 and 30/39 (77%) for HPV18. Two vaccinated participants were seronegative for HPV16/18; both had detectable HIV viral loads and CD4 counts
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Imperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK.
- Imperial College Healthcare NHS Trust, London, UK.
- NIHR Imperial Biomedical Research Centre (BRC).
- Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency, London, UK.
- Blood Safety, Hepatitis, STI and HIV Division, UK Health Security Agency, London, UK.
- Cervical Screening London, Health Services Laboratories, London, UK.
ORCID-Profile: Caroline Foster, Tamara Elliott
Förderung
- British HIV Association
- Imperial Health Charity
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Henderson, M., Lyons, D., Beddows, S., Cowen, M., Panwar, K., Wright, C., Ujetz, J., Crook, E., Patel, H., Smith, D., Foster, C., Fidler, S., & Elliott, T. (2025). High‐risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV. HIV Medicine. https://doi.org/10.1111/hiv.70001
Vancouver
Henderson M, Lyons D, Beddows S, Cowen M, Panwar K, Wright C, et al. High‐risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV. HIV Medicine. 2025. doi:10.1111/hiv.70001
BibTeX
@article{Henderson2025,
author = {Henderson, Merle and Lyons, Dierdre and Beddows, Simon and Cowen, Miranda and Panwar, Kavita and Wright, Corrina and Ujetz, Jacquie and Crook, Ellie and Patel, Hasit and Smith, David and Foster, Caroline and Fidler, Sarah and Elliott, Tamara},
title = {High‐risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70001}
}
EUVIMED